HPgV-2
human pegivirus
HPgV-2 (also known as human pegivirus type 2) is the second human pegivirus discovered. It was first identified in 2005 in blood of transfusion recipients and initially named hepegivirus 1 because it shared some genetic features with both pegiviruses and hepaciviruses. HPgV-2 was later independently discovered by another group in the blood of a HCV-infected patient who had undergone multiple blood transfusions and died from sepsis of unclear etiology. It was then named human pegivirus 2. HPgV-2 is now classified in the Pegivirus genus as part of Pegivirus columbiaense species.
HPgV-2 is a blood-borne virus that causes chronic long-term infections much like hepatitis C virus (HCV) and GB virus C (HPgV) – the first human pegivirus to have been discovered – but is not known to be associated with any disease. It usually infects people who are already infected by HCV and has the prevalence around 1–2% in such persons. Its prevalence in HCV/HIV coinfected subjects is still higher – up to 10%. However, its prevalence in the general population in China and USA is very low at 0.1–0.2%. The chronic infection by HPgV-2 is maintained in presence of antienvelop antibodies as is the case for HCV chronic infections, whereas in case of GB virus C, appearance of antibodies usually leads to resolution of the infection.
This brief starts where responsible research should: with the source description of “HPgV-2” as human pegivirus. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the general reference register because the source frames it as human pegivirus. Its deeper value depends on whether names, dates, institutions and citations support that framing.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Mar 25, 2026. The linked authority identifier is Q49000682. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2005.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “HPgV-2”, its source revision and the description used here.
- Expand the search: follow HPgV-2 primary sources, HPgV-2 archive and HPgV-2 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “HPgV-2”?
- Which institution is responsible for the underlying evidence?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “HPgV-2” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.